Red Light Holland (TRIP) AI Stock Analysis

• Market Cap: C$10.64M
• Dividend Yield: N/A
• Average Volume (3M): 212.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: -28.00%
• EPS Growth: 38.46%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 425,710,720
• 10 Day Avg. Volume: 258,444
• 30 Day Avg. Volume: 212,422
• PEG Ratio: -0.09
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 4.99
• P/FCF Ratio: -6.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: C$0.03 ▲(25.00% Upside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

The score is held back primarily by weak financial performance—persistent losses and negative operating/free cash flow—despite strong revenue growth and a relatively solid, low-leverage balance sheet. Technicals add modest support from strong momentum, while valuation remains constrained by loss-making earnings and the absence of a dividend yield.

Positive Factors

Low-leverage balance sheet

Low leverage and sizable equity provide durable financial flexibility, lowering bankruptcy risk and enabling the company to absorb short-term losses or fund strategic initiatives. This strengthens the company's ability to navigate regulatory complexity in psychedelics and invest in capacity or compliance.

Revenue traction

Material revenue scaling indicates product-market fit and growing consumer adoption in permitted markets. Sustained top-line growth creates a foundation for operating leverage and margin improvement over months, assuming management controls operating costs and converts demand into higher-margin channels.

Established legal-market operations and brand

Operating in a legalized jurisdiction with branded microdosing products gives a structural advantage: regulatory know-how, production experience, and first-mover brand presence. This durable positioning supports long-term channel relationships, product development, and scaling in other permitted markets.

Negative Factors

Negative operating and free cash flow

Sustained negative operating and free cash flow reduces self-funding ability and forces reliance on external financing, increasing dilution or interest burden. Over months this constrains strategic investments, limits runway for commercialization, and raises execution risk if capital access tightens.

Persistent unprofitability and weak margins

Despite positive gross margins, operating losses signal structural cost or SG&A inefficiencies preventing conversion of revenue into profit. If operating cost base isn't reduced or revenue mix shifted to higher-margin channels, profitability may remain elusive over the medium term.

Negative returns erode equity over time

Strongly negative ROE indicates the company is destroying shareholder capital; continued losses can materially weaken the equity buffer that currently provides protection. Over several months this increases balance-sheet vulnerability and could impair future financing terms or growth capacity.

Red Light Holland Business Overview & Revenue Model

Company Description

Red Light Holland Corp. (TRIP) is a Canadian company focused on the production and distribution of psilocybin truffles, marketed primarily for recreational and therapeutic use. Operating in the emerging psychedelics sector, Red Light Holland aims to provide high-quality, safe, and consistent products to consumers, leveraging a strong brand presence and innovative cultivation methods. The company is also engaged in education and advocacy efforts surrounding responsible use and the potential benefits of psychedelics.

How the Company Makes Money

Red Light Holland primarily makes money by selling legal psilocybin truffle products and related branded offerings in jurisdictions where they are permitted, with its core commercial activity centered on the Netherlands’ legal market for psilocybin-containing truffles. Revenue is generated through (1) direct-to-consumer and/or retail distribution sales of packaged truffles and microdosing-oriented products sold under company brands, and (2) wholesale or business-to-business supply where applicable, by producing truffles and supplying finished or bulk products into legal sales channels. The company’s earnings are influenced by its ability to cultivate and manufacture at scale, maintain compliant distribution in regulated markets, and build consumer demand through brand, product formats (e.g., microdosing), and marketing in permitted regions. Specific breakdowns of revenue by channel, named major customers, or material partnership-driven revenue contributions are null.

Red Light Holland Financial Statement Overview

Summary

Strong revenue scaling and a low-leverage balance sheet are positives, but they are outweighed by deeply negative net income and continued negative operating/free cash flow, indicating the business has not yet converted growth into sustainable profitability or self-funding operations.

Income Statement

Revenue has scaled up materially over time, with TTM (Trailing-Twelve-Months) revenue up sharply versus the prior annual period, showing demand traction. However, profitability remains weak: TTM (Trailing-Twelve-Months) net income is deeply negative and margins are still materially below zero (operating and net), indicating the business has not yet converted growth into sustainable earnings. Gross margin is positive and decent in TTM (Trailing-Twelve-Months), but operating costs continue to overwhelm gross profit.

Balance Sheet

The balance sheet is a relative strength, with low leverage: TTM (Trailing-Twelve-Months) debt is small versus equity and the debt-to-equity ratio is very low. Equity remains sizable, providing financial flexibility and some downside protection. The key weakness is value creation: return on equity is strongly negative in TTM (Trailing-Twelve-Months), reflecting ongoing losses that can erode the equity base over time if not corrected.

Cash Flow

Cash generation remains pressured, with TTM (Trailing-Twelve-Months) operating cash flow and free cash flow both negative, implying the company is still cash-burning. A positive sign is that free cash flow has improved versus the prior annual period (strong positive growth rate), suggesting the burn rate may be moderating. Still, cash flow has not yet turned self-funding, and negative operating cash flow reduces flexibility without external financing.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Mar 2020
Income Statement
Total Revenue	4.17M	4.94M	4.75M	3.95M	2.33M	0.00
Gross Profit	1.27M	1.91M	2.02M	1.71M	617.68K	0.00
EBITDA	-4.36M	-3.35M	-6.58M	-4.32M	-8.55M	0.00
Net Income	-4.77M	-4.04M	-7.63M	-5.40M	-14.37M	-325.17K
Balance Sheet
Total Assets	18.20M	21.22M	24.08M	30.14M	32.94M	3.97M
Cash, Cash Equivalents and Short-Term Investments	9.88M	12.27M	14.17M	18.53M	26.62M	1.96M
Total Debt	501.66K	2.18M	1.72M	1.77M	1.50M	86.77K
Total Liabilities	3.58M	3.87M	3.82M	3.80M	3.78M	5.11M
Stockholders Equity	14.69M	17.35M	20.07M	26.06M	28.48M	-1.14M
Cash Flow
Free Cash Flow	-2.69M	-2.01M	-3.92M	-6.45M	-5.28M	-238.35K
Operating Cash Flow	-2.51M	-1.48M	-3.23M	-4.39M	-4.88M	-238.35K
Investing Cash Flow	-1.16M	-525.40K	-650.43K	-3.17M	-582.74K	-1.80M
Financing Cash Flow	-490.68K	445.17K	-206.95K	-114.16K	451.76K	4.01M

Red Light Holland Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TRIP, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.65 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:TRIP.

Red Light Holland Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MUSH	54 Neutral	C$7.49M	-7.07	-99.55%	―	-26.71%	-988.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CWEB	51 Neutral	C$157.83M	-1.15	-119.94%	―	-4.23%	37.33%
TRIP	50 Neutral	C$10.64M	-1.51	-23.76%	―	-28.00%	38.46%
CURA	50 Neutral	C$2.33B	-8.05	-28.58%	―	-3.38%	-31.35%
RVV	47 Neutral	C$18.84M	-4.56	899.59%	―	―	-80.42%
PLTH	42 Neutral	C$65.07M	-0.45	-90.71%	―	2.19%	-91.41%

Red Light Holland Corporate Events

Red Light Holland Deploys Kala Bio AI Platform to Advance Psilocybin Drug PEX010

Red Light Holland has engaged Kala Bio’s Researgency.ai platform to support clinical development of PEX010, Filament Health’s patented botanical psilocybin drug candidate. The AI-driven system will assist with clinical planning, protocol optimization and scenario modeling as Red Light integrates Filament’s assets and advances PEX010 through its regulated development pipeline.

The move is positioned as a key step in building a best-in-class psychedelic drug development operation, aiming to compress timelines and improve study design quality for one of the most widely studied botanical psilocybin candidates. By adopting purpose-built agentic AI for biotechnology workflows, Red Light aligns with a broader industry shift toward specialized AI infrastructure in drug development, potentially strengthening its competitive position in the emerging psychedelic therapeutics market.

Kala Bio’s Researgency.ai platform, operated under an exclusive worldwide license, enables secure, autonomous research loops that generate and optimize study scenarios at scale. Applied to PEX010, which is already authorized for trials by Health Canada and the U.S. Food and Drug Administration and has positive Phase 2 data in alcohol use disorder, the technology is expected to enhance how clinical strategies are evaluated across multiple indications and research institutions.

The most recent analyst rating on (TSE:TRIP) stock is a Sell with a C$0.03 price target. To see the full list of analyst forecasts on Red Light Holland stock, see the TSE:TRIP Stock Forecast page.

Red Light Holland Narrows Focus as Q3 Revenue Rises but Profits Tighten

Red Light Holland reported third-quarter 2026 results showing an 8.3% year-over-year revenue increase to $1.27 million, but a 13.7% decline in gross profit and a slightly higher adjusted EBITDA loss of $0.71 million, while cash fell to $9.24 million amid investment in Bitcoin ETFs and high-interest savings vehicles. Management highlighted normalized sales versus the prior quarter, lower G&A expenses, the shutdown of shiitake mushroom production at AEM to focus on near-profitable operations, and progress in psilocybin R&D through its DEA-registered partner Irvine Labs, underscoring a strategic pivot toward an R&D-driven model and active evaluation of M&A from a relatively strong balance-sheet position.

The most recent analyst rating on (TSE:TRIP) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Red Light Holland stock, see the TSE:TRIP Stock Forecast page.